



Media Contact:

Nicole Osmer

nicole@nicleosmer.com

(650) 454-0504

Clinical Study Featuring Tryton Stent Wins Best Abstract Award at Italian Society of Interventional Cardiology National Congress (GISE) in Genoa, Italy

Live Case Transmission During Conference Demonstrates Ease-of-Use of Tryton Stent System

Durham, N.C. – Nov. 2, 2010 – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that an abstract reporting results from the company’s Tryton stent system was recognized as the best presented at the Italian Society of Interventional Cardiology National Congress (GISE) in Genoa, Italy.

The winning abstract was authored by Filippo Russo M.D., Giuseppe de Nittis, M.D., Elena Butti, M.D., Santo Claudio Zerboni, M.D., Carlo Campana, M.D., and Mario Galli, M.D., of Ospedale Sant’Anna in Como, Italy.

The authors conclude that preliminary data suggest that “treatment with Tryton is safe and associated with good mid-term outcomes; this technique appears simpler than other ones... and associated with better results.”

The study enrolled 33 patients with coronary artery disease. The primary endpoint was achieved in all cases; no patients experienced a major adverse cardiac event during hospitalization and at 30 days.

"Tryton congratulates Dr. Galli and his colleagues on this winning abstract," said J. Greg Davis, president and CEO of Tryton Medical. "We are pleased that the Tryton Stent System is emerging as the preferred treatment for bifurcation lesions, as evidenced by the conclusion of the abstract."

A live case transmission featuring the Tryton stent in the treatment of a complex bifurcation lesion performed by Dr. Roberto Bonmassari, M.D., of Ospedale Santa Chiara, Trento, went smoothly and was well received by the more than 400 cardiologist participants.

TRYTON MEDICAL, INC.

1000 Park Forty Plaza, Suite 325

Durham, NC 27713

PHONE 919 / 226.1490

FAX 919 / 226.1497

info@trytonmedical.com

trytonmedical.com

The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. Tryton's highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

The stent system has received CE Mark approval in Europe and is commercially available in 21 countries throughout Europe and the Middle East. It is not approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (Professor of Medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. The Tryton Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. Privately held, Tryton is backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.

###